Citations 1
Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
Durrant, S. T. S., Harrison, Claire , He, Shui, Garrett, William M., Li, Jingjin , Pirron, Ulrich, Lawniczek, Tomasz, Verstovšek, Srđan , Kiladjian, Jean‐Jacques , Grießhammer, Martin , Masszi, Tamás , Passamonti, Francesco , Pane, Fabrizio , Zachée, Pierre , Mesa, Ruben A. , Jones, Mark, Vannucchi, Alessandro M.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7026-7026
